Description: Niche low-frequency RFA options are carving space in the France Radiofrequency Ablation Devices Market, suiting specialized needs.

The France Radiofrequency Ablation Devices Market persists robustly in October 2025, valued at USD 274.8 million in 2024 and targeting USD 578.8 million by 2035 at 7.01% CAGR through 2025-2035. Low-frequency ablation, at 28% tech share, appeals for gentler waveforms in sensitive pain and gastro apps, avoiding thermal spikes in 150,000 annual nerve blocks. CNAM's 2025 reimbursement tweaks for low-freq devices have lifted usage 18% in clinics, especially Normandy's pain centers.

It complements high-freq in multiples for oncology hybrids, accessories adapting waveforms. End-users split: hospitals 50%, ASCs 30% for portability.

Gaining ground, the low-frequency options through NeuroTherm's variable-pulse probes enhance durability. B. Braun's integrations yielded 13% growth, tackling depth control. Opportunities in biofeedback loops could double share, offsetting higher-freq dominance. Low-freq thus diversifies, improving tolerance.

Adaptive low-freq will niche-expand.

#lowfrequencyrfa #gentleablation #francelowfreq #nervetreatment #waveformtech